Medmix Ag · SIX:MEDX
Medmix — September 2023 equities conferences
23 slides from Medmix's conference presentation, September 2023
Slide 1: medmix
medmix CONFIDENTIAL
Slide 2: Investor Presentation September 2023
Investor Presentation September 2023 medmix CONFIDENTIAL
Slide 3: The safe harbor statement under the US private securities litigation reform act 1995
The safe harbor statement under the US private securities litigation reform act 1995 This presentation contains forward-looking statements that are based on management’s current assumptions and expectations concerning future developments, including but not limited to, projections of financial develo
Slide 4: Our aspiration and mission
Our aspiration and mission ASPIRATION Be the global leader in high precision delivery devices for the healthcare, consumer and industrial end-markets MISSION Providing innovative solutions to help millions of people live a healthier and more confident life 4
Slide 5: Our values
Our values Customer Focus We develop, manufacture and market products and solutions that meet our customers’ needs more effectively than the competition. Trust and Teamwork We build trust by an open, honest, and effective collaboration with each other. Sustainable Innovation We bring innovation to l
Slide 6: medmix at a glance
medmix at a glance Global 15 CHF footprint 477m revenue in 2022 production, logistics and ~2.4bn distribution sites ~2,600 Products per year ~900 22% active patents adj. EBITDA employees margin 6 medmix CONFIDENTIAL
Slide 7: Segment market trends
Segment market trends Underpinned by attractive fundamental macro trends Market growth forecast post Macro trends recovery to 2027E (CAGR)1 Main segment trends • Aging population Growing Dental middle-class market 2% • Emerging markets shift away from hand- to device-mixing • Trend to unit-dose to a
Slide 8: Revenues and growth by market segment
Revenues and growth by market segment Healthcare Business Area (“BA”) Consumer & Industrial BA ("C&I") Drug Dental Surgery Industry Beauty Delivery FY22 125.1 +5.8%2 47.0 +21.4% 12.8 +1.3% 148.2 -8.2% 144.1 +18.6% HY23 53.7 +1%3 26.9 +21% 8.6 +42% 72.7 +6% 86.3 +21% • Tough H1 2022 comps • Strong pr
Slide 9: Business Review
Business Review medmix CONFIDENTIAL
Slide 10: Half year 2023 highlights
Half year 2023 highlights • Double-digit growth rates at both Group and the Business Area organic revenue and profit level against H2 2022 • Revenue of CHF 248.1 million, +9.5% • Business Area Gross Margin improved by 50 bps to 43.8% • Adjusted EBITDA of CHF 49.7 million, +9.7%1 • Dental: customer i
Slide 11: Industry production recovery
Industry production recovery Everything everywhere all at once Mitigating (from April 2022) Relocating (from July 2022) Customer loyalty and trust Task force meeting 3x / week Future-proofing (from now) Relocation team identifying Intensive sales planning processes, personnel, plant Showcase Industr
Slide 12: Industry production recovery
Industry production recovery Empty shell to functioning factory within six months - Valencia Crane installed – Infrastructure construction ongoing Production office ongoing Production and Assembly ready 12 medmix CONFIDENTIAL
Slide 13: ESG at medmix in H1 2023
ESG at medmix in H1 2023 Sustainability-focused innovation | New gender equality initiative medmix Group Beauty Industry • 70% reduction vs. 2019 achieved in medmix-own1 carbon footprint • Accepted into UN Global Compact • Signatories to 7 UN Women’s • New sustainable shadow • Launch in June 2023 of
Slide 14: Financial Review
Financial Review Jennifer Dean CFO medmix CONFIDENTIAL
Slide 15: 2022 Results
2022 Results Growth and resilience • Revenue growth above top end of adjusted guidance 1 Key Figures 2022 2021 YoY adj.1 Correcting for Poland YoY growth +11.8% Revenue 477.1 457.3 4.3% 5.7% • BA Gross Profit Margin % -250 bps YoY driven by: - time lag in price increases v cost inflation Business Ar
Slide 16: H1 2023 results – key figures
H1 2023 results – key figures Stalled growth, adverse mix and capex depress KPIs in short term Key Figures H1’23 vs. H1’22 vs. H2’22 • Group revenues up on organic basis Revenue 248.1 -1.0% +9.5% • Lower volumes in Dental and Industry Organic revenue growth – +1.3% +12.2% weighing on gross profit BA
Slide 17: Healthcare
Healthcare Growth across all Healthcare Segments Key Figures 2022 2021 YoY1 Revenue split Revenue 184.9 169.8 9.2% Surgery 7% Business Area Gross Profit 112.7 103.2 9.5m (2021: 8%) Business Area Gross Profit margin % 61.0% 60.8% +0.2pts • Healthcare represented 39% of medmix revenue in 2022 (37% Dru
Slide 18: Consumer & Industrial
Consumer & Industrial Growth in Beauty and resilience in Industry Key Figures 2022 2021 YoY1 Revenue split Revenue 292.3 287.5 +3.6% Business Area Gross Profit 105.3 117.1 -11.8m Business Area Gross Profit margin % 36.0% 40.7% -4.7pts • Revenue up 3.6% YoY due to successful launch of new Industry pr
Slide 19: Outlook
Outlook medmix CONFIDENTIAL
Slide 20: Outlook
Outlook FY 2023 guidance Mid-term outlook1 • Organic revenue growth 5% to 7%2 • Organic revenue growth 8%2 • Adjusted EBITDA margin of around • Adjusted EBITDA margin of 30%2 22% (vs. 23% previously) Organic growth guidance range confirmed due Over longer term, medmix benefits from to expected norma
Slide 21: Outlook - segments
Outlook - segments Healthcare Consumer and Industrial ("C&I") Drug Dental Surgery Industry Beauty Delivery Demand expected to be Outlook supported by Expected growth ahead Outlook supported by key Market forecast supports in line with market current project pipeline of market forecast from industrie
Slide 22: Outlook - Drug Delivery
Outlook - Drug Delivery Expected revenue development Current projects delivering product revenues in 2026 by clinical stage +29% Phase 2 Phase 3 Market Authorization Expected 2026 product revenues by indication (based on current serial products and current projects) Growth disorders and related Fert
Slide 23: Your Investor Relations contact
Your Investor Relations contact Sheel Gill Head of M&A, Strategy and Investor Relations, medmix Phone: +41 41 723 73 57 Mobile: +41 79 346 41 72 E-mail: investorrelations@medmix.com medmix Group AG Neuhofstrasse 20 6340 Baar Switzerland 23 medmix CONFIDENTIAL